Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
11 January 2022 - 12:00AM
Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial
Biology Company®, today announced preliminary unaudited revenue for
the fourth quarter and full year ended December 31, 2021.
Akoya reported the following preliminary financial results for
the fourth quarter and full year 2021, which remain subject to
quarter end closing adjustments:
- Revenue for the fourth quarter of 2021 is expected to be
between $16.0 million and $16.2 million, as compared to $12.9
million for the corresponding quarter of last year
- For the fiscal year of 2021, revenue is expected to be between
$54.8 million and $55.0 million, as compared to $42.4 million for
fiscal year 2020
“The fourth quarter of 2021 was a record revenue quarter for
Akoya and it demonstrates continued momentum in our business,” said
Brian McKelligon, Chief Executive Officer. “We made significant
progress in 2021 on a number of major initiatives, including our
IPO in April, approximately 30% growth in revenues, nearly doubling
the company’s headcount with specific emphasis on the commercial
and R&D organizations, and announcement of our new 2022 product
offerings at our inaugural Spatial Day on December 15, 2021. We
enter 2022 with tremendous confidence in our strategy as we drive
adoption of our spatial biology platforms to our research,
translational and clinical customers.”
A link to a webcast replay of Akoya’s inaugural Spatial Day,
which took place virtually on December 15, 2021, can be found
below:
Akoya Spatial Day 2021 | Akoya (akoyabio.com)
The financial results in this press release reflect expectations
based on currently available information. The company has yet to
complete its quarter end closing and actual results are therefore
subject to change.
Use of forward-looking statements
This press release contains forward-looking statements that are
based on management’s beliefs and assumptions and on information
currently available to management. All statements contained in this
release other than statements of historical fact are
forward-looking statements, including statements regarding our
fourth quarter 2021 revenue outlook.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under the captions "Risk Factors," and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" in our Registration Statement on Form F-1
filed with the U.S. Securities and Exchange Commission and
elsewhere in the documents we file with the Securities and Exchange
Commission from time to time. We caution you that forward-looking
statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. As a result, the forward-looking
statements may not prove to be accurate. The forward-looking
statements in this press release represent our views as of the date
hereof. We undertake no obligation to update any forward-looking
statements for any reason, except as required by law.
About Akoya BiosciencesAs The Spatial Biology
Company®, Akoya Biosciences’ mission is to bring context to the
world of biology and human health through the power of spatial
phenotyping. The company offers comprehensive single-cell imaging
solutions that allow researchers to phenotype cells with spatial
context and visualize how they organize and interact to influence
disease progression and treatment response. Akoya offers two
distinct solutions, the CODEX® and Phenoptics™ platforms, to serve
the diverse needs of researchers across discovery, translational
and clinical research.
Investor Contact:Priyam ShahAkoya
Biosciencesinvestors@akoyabio.com
Media Contact:Michelle LinnBioscribe,
Inc.774-696-3803michelle@bioscribe.com
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akoya BioSciences (NASDAQ:AKYA)
Historical Stock Chart
From Apr 2023 to Apr 2024